+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
FEMALE
ID05542407

Phase 1 Study of ONC201 and Atezolizumab Treatment for Obesity-Related Advanced Endometrial Cancer

Led by UNC Lineberger Comprehensive Cancer Center · Updated on 2026-01-29

58

Participants Needed

1

Research Sites

23 weeks

Total Duration

AI-Summary

What This Trial Is About

Endometrial cancer is a common cancer among women in the United States, with rising cases and mortality linked to obesity. This trial studies a combination of two treatments, atezolizumab and ONC201, to explore their safety in treating advanced or recurrent endometrial cancer. The study focuses on both obese and non-obese patients to better understand how obesity affects the disease and treatment response. Participants receive atezolizumab intravenously on the first day of each 21-day cycle, with doses based on body weight. ONC201 is given orally once or twice a week in doses ranging from 375 mg to 625 mg. The study includes two groups those with a body mass index BMI over 30 and those with a BMI 29.9 or lower. This Phase 1 trial aims to find the recommended dose for future studies. During the study, participants undergo regular assessments to track tumor response, survival rates, and treatment safety for up to two years. Researchers measure the recommended Phase 2 dose within three weeks of starting treatment. Patients are monitored through imaging, laboratory tests, and physical exams to evaluate disease progression and overall health. The study is non-randomized and does not use masking, allowing close observation of treatment effects in each group.

CONDITIONS

Brief Title

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Research Team

D

De'Andrea Taylor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here